source
- Eli Lilly partners with Ascidian Therapeutics on $1.9 b RNA exon-editing collaboration for kidney diseaseEli Lilly and Boston-based Ascidian Therapeutics announced a research collaboration aimed at discovering medicines for genetically driven kidney diseases. The partnership leverages Ascidian’s RNA e…
- Alnylam inks up to $2 billion AI partnership with Inceptive Nucleics for RNAi drug discoveryAlnylam announced a three-year strategic collaboration with Inceptive Nucleics to develop AI foundation models for RNAi therapeutics. The agreement is valued at up to $2 billion, with an initial $…